Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib + Zoledronic Acid in Breast Cancer with Bone Metastasis
NCT00566618Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2007
- Primary completion
- Nov 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in breast cancer, sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2007; status: completed.
02
Drugs
dasatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00566618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00566618.